James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Overman, MJ, Modak, J, Kopetz, S, Murthy, R, Yao, JC, Hicks, ME, Abbruzzese, JL, and Tam, AL. "Use of research biopsies in clinical trials: are risks and benefits adequately discussed?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, no. 1 (January 2013): 17-22.

PMID
23129736
Full Text

Katz, MHG, Fleming, JB, Bhosale, P, Varadhachary, G, Lee, JE, Wolff, R, Wang, H, Abbruzzese, J, Pisters, PWT, Vauthey, J-N, Charnsangavej, C, Tamm, E, Crane, CH, and Balachandran, A. "Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators." Cancer 118, no. 23 (December 2012): 5749-5756.

PMID
22605518
Full Text

Weng, S, Wang, H, Chen, W, Katz, MH, Chatterjee, D, Lee, JE, Pisters, PW, Gomez, HF, Abbruzzese, JL, Fleming, JB, and Wang, H. "Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21, no. 8 (August 2012): 1336-1343.

PMID
22665577
Full Text

Wang, J, Estrella, JS, Peng, L, Rashid, A, Varadhachary, GR, Wang, H, Lee, JE, Pisters, PWT, Vauthey, J-N, Katz, MH, Gomez, HF, Evans, DB, Abbruzzese, JL, Fleming, JB, and Wang, H. "Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation." Cancer 118, no. 15 (August 2012): 3801-3811.

PMID
22180096
Full Text

Truty, MJ, Thomas, RM, Katz, MH, Vauthey, J-N, Crane, C, Varadhachary, GR, Wolff, RA, Abbruzzese, JL, Lee, JE, and Fleming, JB. "Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration." Journal of the American College of Surgeons 215, no. 1 (July 2012): 41-51.

PMID
22608401
Full Text

Chatterjee, D, Katz, MH, Rashid, A, Varadhachary, GR, Wolff, RA, Wang, H, Lee, JE, Pisters, PWT, Vauthey, J-N, Crane, C, Gomez, HF, Abbruzzese, JL, Fleming, JB, and Wang, H. "Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome." Cancer 118, no. 12 (June 2012): 3182-3190.

PMID
22028089
Full Text

Dong, X, Li, Y, Chang, P, Hess, KR, Abbruzzese, JL, and Li, D. "DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer." Molecular carcinogenesis 51, no. 6 (June 2012): 491-499.

PMID
21681824
Full Text

Overman, MJ, Hu, C-Y, Kopetz, S, Abbruzzese, JL, Wolff, RA, and Chang, GJ. "A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease." Annals of surgical oncology 19, no. 5 (May 2012): 1439-1445.

PMID
22187121
Full Text

Tomblyn, MB, Goldman, BH, Thomas, CR, Benedetti, JK, Lenz, H-J, Mehta, V, Beeker, T, Gold, PJ, Abbruzzese, JL, Blanke, CD, and SWOG GI Committee, . "Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 7, no. 5 (May 2012): 906-912.

PMID
22481235
Full Text

Friday, B, Lassere, Y, Meyers, CA, Mita, A, Abbruzzese, JL, and Thomas, MB. "A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors." Anticancer research 32, no. 5 (May 2012): 1689-1696.

PMID
22593447
Scholars@Duke

Pages